Literature DB >> 33881127

Tissue metabolic profiling reveals major metabolic alteration in colorectal cancer.

Yao Shen1, Mao Sun, Jun Zhu, Mengying Wei, Huichen Li, Pan Zhao, Jiajia Wang, Ruikai Li, Lianlian Tian, Yanyan Tao, Peng Shen, Jian Zhang.   

Abstract

Metabolic reprogramming is a hallmark of cancer, which is still far from being fully understood in colorectal cancer. In order to characterize the metabolic changes in colorectal cancer, we performed metabolomics analysis of paired colon tissues from colorectal cancer patients by using a liquid chromatography-mass spectrometry (LC-MS)-based method. Bioinformation analysis was used to define important metabolites and metabolic pathways, as well as the prognosis significance and expression levels of the key molecules. The results indicated that the metabolite phenotype in cancerous colon tissues was obviously different from their normal counterpart, and we identified a series of important metabolic changes in colorectal cancer, including decreased trends of glucose, citrate, serotonin, 5-hydroxytryptophol and 5-hydroxyindoleacetate, as well as increased trends of glutamate, glutathione, creatine, proline, lactate, fructose 1,6-bisphosphate, succinate, tryptophan, kynurenine and long chain acyl-carnitines. These metabolites are mainly implicated in energy metabolism, amino acid metabolism, glutathione metabolism and fatty acid metabolism. In addition, we found that the expression levels of several key molecules in these pathways were closely correlated with the prognosis of colorectal cancer patients. This study characterizes the metabolic profile in colorectal cancer tissues and provides more insightful understanding of the metabolic reprogramming of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33881127     DOI: 10.1039/d1mo00022e

Source DB:  PubMed          Journal:  Mol Omics        ISSN: 2515-4184


  5 in total

1.  KAT2A affects tumor metabolic reprogramming in colon cancer progression through epigenetic activation of E2F1.

Authors:  Xiaofeng Han; Jie Chen
Journal:  Hum Cell       Date:  2022-05-18       Impact factor: 4.174

2.  Discovery of Synergistic Drug Combinations for Colorectal Cancer Driven by Tumor Barcode Derived from Metabolomics "Big Data".

Authors:  Bo Lv; Ruijie Xu; Xinrui Xing; Chuyao Liao; Zunjian Zhang; Pei Zhang; Fengguo Xu
Journal:  Metabolites       Date:  2022-05-30

3.  Metabolomic Profiling Identified Serum Metabolite Biomarkers and Related Metabolic Pathways of Colorectal Cancer.

Authors:  Chengjian Zhang; Shengnan Zhou; Huijing Chang; Feng Zhuang; Yang Shi; Le Chang; Wanchao Ai; Juan Du; Wei Liu; Humin Liu; Xukun Zhou; Zhong Wang; Tao Hong
Journal:  Dis Markers       Date:  2021-12-07       Impact factor: 3.434

Review 4.  Emerging role of non-coding RNAs in glucose metabolic reprogramming and chemoresistance in colorectal cancer.

Authors:  Shushan Yan; Shufeng Wang; Xinyi Wang; Wenqing Dai; Jinjin Chu; Min Cheng; Zhiliang Guo; Donghua Xu
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

5.  The Effectiveness of Glutathione Redox Status as a Possible Tumor Marker in Colorectal Cancer.

Authors:  Delia Acevedo-León; Lidia Monzó-Beltrán; Segundo Ángel Gómez-Abril; Nuria Estañ-Capell; Natalia Camarasa-Lillo; Marisa Luisa Pérez-Ebri; Jorge Escandón-Álvarez; Eulalia Alonso-Iglesias; Marisa Luisa Santaolaria-Ayora; Araceli Carbonell-Moncho; Josep Ventura-Gayete; Luis Pla; Maria Carmen Martínez-Bisbal; Ramón Martínez-Máñez; Leticia Bagán-Debón; Aurora Viña-Almunia; M Amparo Martínez-Santamaría; María Ruiz-Luque; Jorge Alonso-Fernández; Celia Bañuls; Guillermo Sáez
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.